Stockholders' Equity (Details) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2022 |
Dec. 15, 2022 |
|
| Stockholders' Equity (Details) [Line Items] | ||||
| Par value per share (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |
| Restricted shares (in Shares) | 600 | |||
| Restricted shares value | $ 8,100 | |||
| Gain (loss) on settlement of liabilities | 557,421 | |||
| General and administrative expenses | 514,696 | $ 5,261 | ||
| Research and development expenses | 81,771 | |||
| Compensation expense | 596,467 | |||
| Common Stock [Member] | ||||
| Stockholders' Equity (Details) [Line Items] | ||||
| General and administrative expenses | 470,703 | |||
| Research and development expenses | 86,718 | |||
| Stock Options [Member] | ||||
| Stockholders' Equity (Details) [Line Items] | ||||
| Unrecognized stock-based compensation expense | $ 2,981,420 | |||
| Weighted average remaining vesting period | 1 year 9 months 18 days | |||
| Restricted Stock [Member] | ||||
| Stockholders' Equity (Details) [Line Items] | ||||
| Unrecognized stock-based compensation expense | $ 9,720 | |||
| Weighted average remaining vesting period | 9 months | |||
| X | ||||||||||
- Definition Restricted shares. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of net gain (loss) on settlement of other claims for entities in bankruptcy, reported as a reorganization item. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The compensation expense recognized during the period pertaining to the deferred compensation arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. No definition available.
|
| X | ||||||||||
- Definition Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense for an underpayment of income taxes. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|